What is eGenesis?
Founded in 2015 and headquartered in Cambridge, Massachusetts, eGenesis is at the forefront of xenotransplantation research. The company leverages advanced gene-editing technologies to develop human-compatible organs, tissues, and cells, effectively bridging the gap between the high demand for organ transplants and the limited supply of human donors. By focusing on the intersection of genomics and therapeutic development, eGenesis occupies a critical niche in the life sciences market, aiming to provide scalable solutions for patients suffering from end-stage organ failure.
How much funding has eGenesis raised?
eGenesis has raised a total of $456M across 5 funding rounds:
Angel/Seed
$2M
Series A
$38M
Series B
$100M
Series C
$125M
Series D
$191M
Angel/Seed (2016): $2M, investors not publicly disclosed
Series A (2017): $38M led by ARCH Venture Partners, Alexandria Equities, Biomatics Capital, Heritage Provider Network, Alta Partners, and Khosla Ventures
Series B (2019): $100M supported by Wellington Partners, Khosla Ventures, Alta Partners, Arch Venture Partners, Biomatics Capital, Leaps by Bayer, and Fresenius Medical Care Ventures
Series C (2021): $125M featuring The Invus Group , LLC, Polaris Partners Pte. Ltd, Samsara BioCapital, HBM Healthcare Investments AG, and Farallon Capital Management , L.L.C.
Series D (2024): $191M backed by Lux Capital, Arch Capital, and Khosla Ventures
Key Investors in eGenesis
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, space, defense, biotechnology, and advanced materials from seed through IPO or acquisition.
Arch Capital
Arch Capital Group Ltd. is a publicly listed Bermuda exempted company that writes insurance, reinsurance and mortgage insurance on a worldwide basis. As an S&P 500 company, Arch is recognized as a leading global financial services company.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, focusing on a broad range of areas including health, biotechnology, and enterprise innovation.
What's next for eGenesis?
With the successful closure of this latest capital injection, eGenesis is well-positioned to accelerate its clinical development programs and scale its manufacturing capabilities. The strategic focus will likely shift toward navigating regulatory pathways and expanding its pipeline of transplantable solutions. As the company matures, the integration of its gene-editing innovations into clinical practice remains the primary objective, supported by a robust network of investors committed to long-term value creation in the healthcare landscape.
See full eGenesis company page
